Squarepoint’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15.9M | Buy |
63,200
+17,500
| +38% | +$3.77M | 0.02% | 816 |
|
|
2026
Q1 | $9.94M | Sell |
45,700
-35,800
| -44% | -$7.94M | 0.01% | 1071 |
|
|
2025
Q4 | $18.6M | Sell |
81,500
-4,600
| -5% | -$1.05M | 0.02% | 772 |
|
|
2025
Q3 | $19.9M | Sell |
86,100
-117,500
| -58% | -$23.9M | 0.02% | 748 |
|
|
2025
Q2 | $37.8M | Sell |
203,600
-23,900
| -11% | -$4.44M | 0.04% | 486 |
|
|
2025
Q1 | $47.7M | Buy |
227,500
+75,600
| +50% | +$14.7M | 0.06% | 362 |
|
|
2024
Q4 | $27M | Buy |
151,900
+31,900
| +27% | +$5.87M | 0.03% | 618 |
|
|
2024
Q3 | $23.7M | Buy |
120,000
+24,400
| +26% | +$4.55M | 0.04% | 520 |
|
|
2024
Q2 | $16.4M | Sell |
95,600
-177,400
| -65% | -$29.4M | 0.03% | 684 |
|
|
2024
Q1 | $49.7M | Buy |
273,000
+263,600
| +2,804% | +$45.4M | 0.09% | 261 |
|
|
2023
Q4 | $1.46M | Sell |
9,400
-15,400
| -62% | -$2.25M | ﹤0.01% | 2246 |
|
|
2023
Q3 | $3.7M | Hold |
24,800
| – | – | 0.01% | 1374 |
|
|
2023
Q2 | $3.34M | Buy |
24,800
+23,400
| +1,671% | +$3.43M | 0.01% | 1324 |
|
|
2023
Q1 | $223K | Sell |
1,400
-39,300
| -97% | -$6.01M | ﹤0.01% | 2743 |
|
|
2022
Q4 | $6.58M | Buy |
40,700
+32,200
| +379% | +$4.94M | 0.03% | 691 |
|
|
2022
Q3 | $1.14M | Sell |
8,500
-8,900
| -51% | -$1.28M | 0.01% | 1674 |
|
|
2022
Q2 | $2.67M | Sell |
17,400
-55,300
| -76% | -$8.45M | 0.01% | 1018 |
|
|
2022
Q1 | $11.8M | Sell |
72,700
-23,200
| -24% | -$3.37M | 0.05% | 397 |
|
|
2021
Q4 | $13M | Sell |
95,900
-2,100
| -2% | -$248K | 0.03% | 439 |
|
|
2021
Q3 | $10.6M | Buy |
98,000
+300
| +0.3% | +$34.3K | 0.03% | 480 |
|
|
2021
Q2 | $11M | Sell |
97,700
-38,300
| -28% | -$4.31M | 0.04% | 436 |
|
|
2021
Q1 | $14.7M | Sell |
136,000
-25,000
| -16% | -$2.67M | 0.09% | 264 |
|
|
2020
Q4 | $17.3M | Buy |
161,000
+158,500
| +6,340% | +$15.2M | 0.13% | 144 |
|
|
2020
Q3 | $219K | Buy |
2,500
+200
| +9% | +$18.8K | ﹤0.01% | 2029 |
|
|
2020
Q2 | $226K | Buy |
+2,300
| New | +$203K | ﹤0.01% | 1765 |
|
|
2020
Q1 | – | Sell |
-2,800
| Closed | -$248K | – | 1794 |
|
|
2019
Q4 | $248K | Sell |
2,800
-12,800
| -82% | -$1.06M | ﹤0.01% | 2128 |
|
|
2019
Q3 | $1.18M | Buy |
15,600
+11,300
| +263% | +$775K | 0.01% | 1112 |
|
|
2019
Q2 | $313K | Buy |
4,300
+200
| +5% | +$15.7K | ﹤0.01% | 1917 |
|
|
2019
Q1 | $330K | Buy |
+4,100
| New | +$335K | ﹤0.01% | 1723 |
|
Other funds holding ABBV
Squarepoint's ABBV Position: Q2 2026 in Review
Squarepoint reduced its AbbVie (ABBV) stake by 53% in Q2 2026, selling an estimated $21.9M and leaving 91,950 shares worth $23.1M. The position accounts for 0.03% of the portfolio, ranked #627.
Squarepoint first reported a position in ABBV in Q3 2015 and has held it in 32 quarters since. The position peaked at $92.1M in Q2 2025. 4,222 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Squarepoint held 91,950 shares of AbbVie worth $23.1M as of Q2 2026.
- Squarepoint sold 101,921 AbbVie shares in Q2 2026, an estimated $21.9M.
- AbbVie made up 0.03% of Squarepoint's portfolio in Q2 2026, its #627 holding.
- Squarepoint first reported a position in AbbVie in Q3 2015 and has held it in 32 quarters since.
- Squarepoint's AbbVie position peaked at $92.1M in Q2 2025.
- 4,222 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.